Dyadic International (OTCMKTS: DYAI) is one of 32 public companies in the “Commercial physical research” industry, but how does it contrast to its competitors? We will compare Dyadic International to related companies based on the strength of its institutional ownership, analyst recommendations, dividends, valuation, risk, profitability and earnings.
Earnings and Valuation
This table compares Dyadic International and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Dyadic International||$760,000.00||-$2.14 million||-11.29|
|Dyadic International Competitors||$968.26 million||$63.67 million||12.50|
Institutional & Insider Ownership
0.0% of Dyadic International shares are owned by institutional investors. Comparatively, 47.2% of shares of all “Commercial physical research” companies are owned by institutional investors. 16.3% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Dyadic International and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Dyadic International Competitors||-300.28%||-87.79%||-35.44%|
This is a breakdown of current ratings and price targets for Dyadic International and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Dyadic International Competitors||125||592||1368||55||2.63|
As a group, “Commercial physical research” companies have a potential upside of 19.12%. Given Dyadic International’s competitors higher probable upside, analysts plainly believe Dyadic International has less favorable growth aspects than its competitors.
Risk and Volatility
Dyadic International has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Dyadic International’s competitors have a beta of 4.22, suggesting that their average share price is 322% more volatile than the S&P 500.
Dyadic International competitors beat Dyadic International on 8 of the 10 factors compared.
About Dyadic International
Dyadic International, Inc., a biotechnology company, engages in the discovery, development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corporation to explore the potential of its C1 technology to produce two vital therapeutic proteins for human health indications; and the Sanofi-Aventis Deutschland GmbH to explore the potential of its C1 technology to produce various types of biologic vaccines and drugs of interest for human health indications. The company was founded in 1979 and is headquartered in Jupiter, Florida.
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.